Patel Sanjiv sold $944K of RLAY
Patel Sanjiv (President and CEO) sold 48,199 shares of Relay Therapeutics, Inc. (RLAY) at $19.58 ($0.94M total) on 2026-07-07 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the record of CEO share sales (48,199 shares for about $943.7K) but does not change the company’s disclosed fundamentals in the text.
Market read
Insider selling can influence sentiment, but 10b5-1 plans usually reduce interpretive value for near-term trading decisions.
What to watch
Traders should check whether the company has concurrent catalysts (earnings, trial readouts, financing) since this filing alone does not provide them.
Background
The article is a SEC Form 4 insider transaction disclosure for Relay Therapeutics, Inc.
Ticker impact
Relay Therapeutics CEO Patel Sanjiv filed a Form 4 selling 48,199 shares at $19.58 on a 10b5-1 plan.
Likely minimal immediate price impact; any reaction is typically short-lived unless accompanied by other new company-specific news.
The filing is a routine insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new operational, financial, or regulatory information.
Market effects
No clear sector read-through; this is company-specific insider activity without new guidance or trial updates.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.
Key entities
- issuerRelay Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderPatel Sanjiv
President and CEO who sold shares under a 10b5-1 plan.
